GSK Receives EU Approval for Nucala in COPD Treatment
ByAinvest
Friday, Feb 6, 2026 11:45 pm ET1min read
GSK--
GSK plc has received EU approval for Nucala as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). The approval is based on the Phase III MATINEE trial, which demonstrated a significant reduction in COPD exacerbations compared to placebo. Nucala is the first biologic to show a reduction in exacerbations leading to emergency department visits and/or hospitalization. COPD affects over 390 million people worldwide, including around 40 million in Europe.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet